SmallCaps Podcast

Leaf Resources (ASX: LER) managing director Ray Mountfort joins Small Caps to discuss the company’s vision to become a global supplier of sustainable natural chemicals. Leaf has developed proprietary technology that converts plant biomass into lignin and industrial sugars for use in the biochemical, bioplastics and biofuel markets. It also recently diversified into the organic pine chemicals manufacturing market with the acquisition of Essential Queensland, which has developed a process to extract rosin and terpenes from pine logs. Leaf is planning to expand its newly commissioned Apple Tree Creek pine chemical plant to boost capacity from 8,000 tonnes per annum to 32,000tpa.

See omnystudio.com/listener for privacy information.

Little Green Pharma (ASX: LGP) managing director Fleta Solomon joins Small Caps to discuss the company’s growth plans with the acquisition of a world class cultivation and GMP medicinal cannabis facility in Denmark. The acquisition is part of Little Green Pharma’s strategy to penetrate the EU with a first mover advantage. A recent $27.2 million placement was significantly supported by mining company Hancock Prospecting which contributed $15 million.

See omnystudio.com/listener for privacy information.

Wellnex Life (ASX: WNX) executive director Zack Bozinovski joins Small Caps to discuss the company’s plans to shake up Australia’s health and wellness market followed by expansion into the trillion dollar global market. The company has relisted on the ASX as part of a strategy to reposition the business which now has more than $20 million in annualised revenues, a diverse brand portfolio and an existing distribution network. Wellnex is eyeing several key markets, including organic, ageing, mental health, energy and sleep.

See omnystudio.com/listener for privacy information.

Koonenberry Gold chairman John Elkington and chief executive officer Karen O'Neill join Small Caps to discuss the company’s IPO and plans for its namesake gold project in New South Wales. The company has defined eight near-drill ready targets within the Koonenberry project including some where gold nuggets have been discovered. Koonenberry’s geology is regarded as similar to that which hosts the Stawell gold mine, one of Victoria’s largest mines, and its nugget field is believed to be larger than Bendigo.

See omnystudio.com/listener for privacy information.

Digital Wine Ventures (ASX: DW8) chief executive officer Dean Taylor joins Small Caps to discuss the company’s record growth as it aims to become the Amazon for wine. The company has agreed to acquire Parton Wine Group which is expected to bolster its WineDepot business’ capability, metrics, revenue and afford a greater competitive advantage. A cloud-based platform, WineDepot is designed to streamline wine and beverage distribution.

See omnystudio.com/listener for privacy information.

Navarre Minerals (ASX: NML) managing director Ian Holland joins Small Caps to discuss the company’s exploration and development plans across its gold portfolio in Victoria. After raising almost $15 million in June and May, Navarre expects exploration and drilling will provide a consistent news flow across the projects. Resource growth is anticipated in the Stawell Corridor and at St Arnaud with a maiden resource of 304,300oz gold announced in March for the Stawell Corridor project.

See omnystudio.com/listener for privacy information.

Nova Minerals (ASX: NVA) chief executive officer Christopher Gerteisen joins Small Caps to discuss the company’s aggressive exploration program underway at its flagship Estelle gold project in Alaska’s Tintina gold belt. Drilling a the Korbel Main deposit has continued to unearth very encouraging gold grades over wide intervals. A fifth rig has been mobilised to site to ramp up drilling at the project which has a growing resource of 4.7Moz gold.

See omnystudio.com/listener for privacy information.

Amplia Therapeutics (ASX: ATX) managing director and CEO John Lambert joins Small Caps to discuss the latest results from the company's clinical trial of its lead drug AMP945.
The pharmaceutical company is aiming to develop new approaches for the treatment of cancer and fibrosis by advancing a pipeline of focal adhesion kinase (FAK) inhibitors.
It recently completed a phase one trial to test the safety and tolerability of AMP945. Amplia now plans to progress to a phase two trial in pancreatic cancer later this year.

See omnystudio.com/listener for privacy information.

Tony Locantro, investment manager at Alto Capital, joins Small Caps to share his views on what's taking place in the stock market, where opportunity may lay and what might come next.

See omnystudio.com/listener for privacy information.

Plenti Group (ASX: PLT) founder and CEO Daniel Foggo joins Small Caps to discuss the company’s mission to become Australia’s best lender. The company’s goal is to have a $1 billion loan portfolio by March next year followed by becoming cash flow positive. To do this, Plenti is in the process of establishing a market leading position within each of its lending segments.

See omnystudio.com/listener for privacy information.